One Step Back, Two Steps Forward: An Economic Evaluation of the PEN Program in Indonesia

REFERENCES

• Lozano R, Naghavi M, Foreman K, Lim S, Shibuya K, Aboyans V, Abraham J, Adair T, Aggarwal R, Ahn SY, et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. The Lancet 2012; 380(9859): 2095-2128.
   PubMed Web of Science ®Google Scholar
• Muka T, Imo D, Jaspers L, Colpani V, Chaker L, van der Lee SJ, Mendis S, Chowdhury R, Bramer WM, Falla A, et al. The global impact of non-communicable diseases on healthcare spending and national income: a systematic review. Eur J Epidemiol 2015; 30(4): 251-277.
   PubMed Web of Science ®Google Scholar
• World Health Organization. Global status report on noncommunicable diseases 2014. Geneva: World Health Organization; 2014.
   Google Scholar
• Bloom DE, Chen S, McGovern M, Prettner K, Candeias V, Bernaert A, Cristin S. Economics of non-communicable diseases in Indonesia. April 2015. Available at http://www3.weforum.org/docs/WEF_The_Economics_of_non_Disease_Indonesia_2015.pdf (accessed 17 August 2015)
   Google Scholar
• National Institute of Health Research and Development. Indonesia basic health research. Jakarta, Indonesia: Ministry of Health; 2010.
   Google Scholar
• Riley L, Cowan M. Noncommunicable diseases country profiles 2014. Geneva: World Health Organization; 2014.
   Google Scholar
• World Health Organization. Package of Essential Noncommunicable (PEN) disease interventions for primary health care in low-resource settings. Geneva: World Health Organization; 2010.
   Google Scholar
• Furie KL, Kasner SE, Adams RJ, Albers GW, Bush RL, Fagan SC, Halperin JL, Johnston C, Katzan I, Kernan WN, et al. Guidelines for the prevention of stroke in patients with stroke or transient ischemic attack: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke 2011; 42(1): 227-276.
   PubMed Web of Science ®Google Scholar
• Qaseem A, Fihn SD, Dallas P, Williams S, Owens DK, Shekelle P. Management of stable ischemic heart disease: summary of a clinical practice guideline from the American College of Physicians/American College of Cardiology Foundation/American Heart Association/American Association for Thoracic Surgery/Preventive Cardiovascular Nurses Association/Society of Thoracic Surgeons. Ann Intern Med 2012; 157(10): 735-743.
   PubMed Web of Science ®Google Scholar
• Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL, Jones DW, Materson BJ, Oparil S, Wright JT, et al. The seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 2003; 289(19): 2560-2572.
   PubMed Web of Science ®Google Scholar
• Rivai LB. Presentation of historical development of PEN program in Indonesia Training Course for PEN evaluation in Indonesia. Jakarta, Indonesia: Ministry of Health; 2015.
   Google Scholar
• American Diabetes Association. Standards of medical care in diabetes 2014. Diabetes Care 2014; 37(Suppl 1): S14-S80.
   PubMed Web of Science ®Google Scholar
• National Health and Medical Research Council. National evidence based guideline for case detection and diagnosis of type 2 diabetes. Canberra, Australia: National Health and Medical Research Council; 2009.
   Google Scholar
• Dukpa W, Teerawattananon Y, Rattanavipapong W, Srinonprasert V, Tongsri W, Kingkaew P, Yothasamut J, Wangchuk D, Dorji T, Wangmo K. Is diabetes and hypertension screening worthwhile in resource-limited settings? An economic evaluation based on a pilot of a Package of Essential Non-communicable disease interventions in Bhutan. Health Policy Plann 2014; 8: 1–12.
   Google Scholar
• Edejer TT-T, Baltussen R, Adam T, Hutubessy R, Acharya A, Evans D, Murray CJL. WHO guide to cost-effectiveness analysis. Geneva: World Health Organization; 2012.
   Google Scholar
• Statistics Indonesia. Estimated population of selected countries (million), 2000–2013 statistics Indonesia. 2012. Available at http://www.bps.go.id/linkTabelStatis/view/id/1284 (accessed 3 April 2015)
   Google Scholar
• Briggs A. Handling uncertainty in cost-effectiveness models. Pharmacoeconomics 2000; 17: 479-500.
   PubMed Web of Science ®Google Scholar
• Ades AE, Claxton K, Sculpher M. Evidence synthesis, parameter correlation and probabilistic sensitivity analysis. Health Econ 2006; 15(4): 373-381.
   PubMed Web of Science ®Google Scholar
• National Institute of Health Research and Development. An unpublished report of Indonesia National Health Survey (RISKESDAS). Jakarta, Indonesia: Ministry of Health; 2013.
   Google Scholar
• Mihardja L, Soetrisno U, Soegondo S. Prevalence and clinical profile of diabetes mellitus in productive aged urban Indonesians. J Diabetes Investig 2014; 5(5): 507-512.
   PubMed Web of Science ®Google Scholar
• Salomon JA, Wang H, Freeman MK, Vos T, Flaxman AD, Lopez AD, Murray CJL. Healthy life expectancy for 187 countries, 1990–2010: a systematic analysis for the Global Burden Disease Study 2010. The Lancet 2013; 380(9859): 2144-2162.
   Web of Science ®Google Scholar
• Pratipanawatr T, Rawdaree P, Chetthakul T, Bunnag P, Ngarmukos C, Benjasuratwong Y, Leelawatana R, Kosachunhanun N, Plengvidhya N, Deerochanawong C, et al. Thailand Diabetic Registry cohort: predicting death in Thai diabetic patients and causes of death. J Med Assoc Thai 2010; 93(Suppl 3): S12-S20.
   PubMedGoogle Scholar
• Somannavar S, Ganesan A, Deepa M, Datta M, Mohan V. Random capillary blood glucose cut points for diabetes and pre-diabetes derived from community-based opportunistic screening in India. Diabetes Care 2009; 32(4): 641-643.
   PubMed Web of Science ®Google Scholar
• Rolka DB, Narayan KMV, Thompson TJ, Goldman D, Lindenmayer J, Alich K, Bacall D, Benjamin EM, Lamb B, Stuart DO, et al. Performance of recommended screening tests for undiagnosed diabetes and dysglycemia. Diabetes Care 2001; 24(11): 1899-1903.
   PubMed Web of Science ®Google Scholar
• Praditsitthikorn N. Economic evaluation of screening for disease. J Med Assoc Thai 2014; 97(Suppl 5): S94-S101.
   PubMedGoogle Scholar
• Lovibond K, Jowett S, Barton P, Caulfield M, Heneghan C, Hobbs FDR, Hodgkinson J, Mant J, Martin U, Williams B, et al. Cost-effectiveness of options for the diagnosis of high blood pressure in primary care: a modelling study. The Lancet 2011; 378(9798): 1219-1230.
   PubMed Web of Science ®Google Scholar
• Leelawattana R, Pratipanawatr T, Bunnag P, Kosachunhanun N, Suwanwalaikorn S, Krittiyawong S, Chetthakul T, Plengvidhya N, Benjasuratwong Y, Deerochanawong C, et al. Thailand Diabetes Registry project: prevalence of vascular complications in long-standing type 2 diabetes. J Med Assoc Thai 2006; 89(Suppl 1): S54-S59.
   PubMedGoogle Scholar
• UK ProspectiveDiabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). The Lancet 1998; 352(9131): 854-865.
   PubMed Web of Science ®Google Scholar
• Srimahachota S, Boonyaratavej S, Kanjanavanit R, Sritara P, Krittayaphong R, Kunjara-Na-ayudhya R, Tatsanavivat P. Thai Registry in Acute Coronary Syndrome (TRACS)—an extension of Thai Acute Coronary Syndrome Registry (TACS) group: lower in-hospital but still high mortality at one-year. J Med Assoc Thai 2012; 95(4): 508-518.
   PubMedGoogle Scholar
• Boussageon R, Bejan-Angoulvant T, Saadatian-Elahi M, Lafont S, Bergeonneau C, Kassai B, Erpeldinger S, Wright JM, Gueyffier F, Cornu C. Effect of intensive glucose lowering treatment on all cause mortality, cardiovascular death, and microvascular events in type 2 diabetes: meta-analysis of randomised controlled trials. BMJ 2011; 343(7817): d4169.
   PubMed Web of Science ®Google Scholar
• Vijan S, Hofer TP, Hayward RA. Cost-utility analysis of screening intervals for diabetic retinopathy in patients with type 2 diabetes mellitus. JAMA 2000; 283(7): 889-896.
   PubMed Web of Science ®Google Scholar
• Coca SG, Ismail-Beigi F, Haq N, Krumholz HM, Parikh CR. Role of intensive glucose control in development of renal end points in type 2 diabetes mellitus: systematic review and meta-analysis intensive glucose control in type 2 diabetes. Arch Intern Med 2012; 172(10): 761-769.
   PubMedGoogle Scholar
• Krittiyawong S, Ngarmukos C, Benjasuratwong Y, Rawdaree P, Leelawatana R, Kosachunhanun N, Plengvidhya N, Deerochanawong C, Suwanwalaikorn S, Pratipanawatr T, et al. Thailand Diabetes registry project: prevalence and risk factors associated with lower extremity amputation in Thai diabetics. J Med Assoc Thai 2006; 89(Suppl 1): S43-S48.
   PubMedGoogle Scholar
• Junrungsee S, Kosachunhanun N, Wongthanee A, Rerkasem K. History of foot ulcers increases mortality among patients with diabetes in northern Thailand. Diabet Med 2011; 28(5): 608-611.
   PubMed Web of Science ®Google Scholar
• Adler AI, Stevens RJ, Manley SE, Bilous RW, Cull CA, Holman RR. Development and progression of nephropathy in type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS 64). Kidney Int 2003; 63(1): 225-232.
   PubMed Web of Science ®Google Scholar
• Blood Pressure Lowering Treatment Trialists' Collaboration. Effects of ACE inhibitors, calcium antagonists, and other blood-pressure-lowering drugs: results of prospectively designed overviews of randomised trials. The Lancet 2000; 356(9246): 1955-1964.
   PubMed Web of Science ®Google Scholar
• International Monetary Fund. The World Economic Outlook Database. April 2015. Available at https://www.imf.org/external/pubs/ft/weo/2015/01/weodata/index.aspx (accessed 2 April 2015)
   Google Scholar
• Brouwer WB, Koopmanschap MA, Rutten FF. Productivity costs in cost-effectiveness analysis: numerator or denominator: a further discussion. Health Econ 1997; 6(5): 511-514.
   PubMed Web of Science ®Google Scholar
• Liljas B, Karlsson GS, Stalhammar NO. On future non-medical costs in economic evaluations. Health Econ 2008; 17(5): 579-591.
   PubMed Web of Science ®Google Scholar
• Weinstein MC, Siegel JE, Garber AM, Lipscomb J, Luce BR, Manning WG Jr, Torrance GW. Productivity costs, time costs and health-related quality of life: a response to the Erasmus Group. Health Econ 1997; 6(5): 505-510.
   PubMed Web of Science ®Google Scholar
• Ministry of Health, Indonesia. An unpublished data of start-up costs for PEN program in Indonesia. Jakarta, Indonesia: Ministry of Health; 2015.
   Google Scholar
• Ministry of Health, Indonesia. Indonesia case base groups (INA-CBGs). Jakarta, Indonesia: Ministry of Health; 2015.
   Google Scholar
• World Health Organization. Global burden of disease 2004 update: disability weights for diseases and conditions. Geneva: World Health Organization; 2004.
   Google Scholar
• Murray CJL, Vos T, Lozano R, Naghavi M, Flaxman AD, Michaud C, Ezzati M, Shibuya K, Salomon JA, Abdalla S, et al. Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010. The Lancet 2012; 380(9859): 2197-2223.
   PubMed Web of Science ®Google Scholar
• Rattanavipapong W, Kumluang S, Luz ACG, Singh D, Teerawattananon Y. Economic evaluation of the WHO Package of Essential Non-communicable disease (PEN) interventions in Indonesia. Nonthaburi, Thailand: Health Intervention and Technology Assessment Program; 2015.
   Google Scholar
• World Health Organization. Global Health Observatory (GHO) data. 2012. Available at http://apps.who.int/gho/data/view.main.60750?lang=en (accessed 3 April 2015)
   Google Scholar